Doctors test 'Living Drug' to fix lungs in groundbreaking trial
NCT ID NCT05761899
Summary
This is the first human trial of a new therapy for hereditary pulmonary alveolar proteinosis (hPAP), a rare lung disease where a genetic flaw stops the lungs from cleaning themselves. Researchers will take a patient's own bone marrow cells, correct the faulty gene in a lab, and transplant the repaired cells back into their lungs. The goal is to see if this one-time treatment is safe and can restore the lung's natural cleaning ability for the long term, replacing the need for repeated, invasive lung washings.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY PULMONARY ALVEOLAR PROTEINOSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cincinnati Children's Hospital Medical Center
RECRUITINGCincinnati, Ohio, 45229, United States
Contact Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.